Is LISATA THERAPEUTICS, INC. (LSTA) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 0.4% / 30% | 84.7% / 30% | 2.4% / 30% | 162.6% / 5% | ✗ NOT HALAL |
| DJIM | 0.4% / 33% | 84.7% / 33% | 2.4% / 33% | 162.6% / 5% | ✗ NOT HALAL |
| MSCI | 0.4% / 33% | 89.3% / 33% | 2.6% / 33% | 162.6% / 5% | ✗ NOT HALAL |
| S&P | 0.4% / 33% | 84.7% / 33% | 2.4% / 33% | 162.6% / 5% | ✗ NOT HALAL |
| FTSE | 0.4% / 33% | 89.3% / 33% | 2.6% / 50% | 162.6% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 100.0% | |
| Operating Margin | -3079.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -75.5% | |
| Return on Assets (ROA) | -43.2% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$16M |
| Free Cash Flow | -$16M |
| Total Debt | $0 |
| Current Ratio | 5.8 |
| Total Assets | $18M |
Price & Trading
| Last Close | $5.02 |
| 50-Day MA | $4.47 |
| 200-Day MA | $2.89 |
| Avg Volume | 180K |
| Beta | 1.3 |
|
52-Week Range
$1.81
| |
About LISATA THERAPEUTICS, INC. (LSTA)
Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product is certepetide, which is in Phase 2 clinical studies for the treatment of solid tumors, such as metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal cancer, and colon cancer and glioblastoma multiforme in combination with range of anti-cancer regimens. The company was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is LISATA THERAPEUTICS, INC. (LSTA) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), LISATA THERAPEUTICS, INC. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is LISATA THERAPEUTICS, INC.'s debt ratio?
LISATA THERAPEUTICS, INC.'s debt ratio is 0.4% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 0.4%.
What are LISATA THERAPEUTICS, INC.'s key financial metrics?
LISATA THERAPEUTICS, INC. has a market capitalization of $45M, and revenue of $170,000. Return on equity stands at -75.5%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.